{
    "studies": [
        {
            "identificationModule": {
                "nctId": "NCT00343668",
                "officialTitle": "A Phase II Study of S-1 and Irinotecan Combination Chemotherapy in Patients With Advanced Gastric Cancer as a First-Line Therapy"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Pathologically proven unresectable adenocarcinoma of stomach\n* With uni-dimensionally measurable disease (at least longest diameter 2 cm on conventional CT scan, x-ray or physical examination, or 1cm on spiral CT scan)\n* Age 18 to 70 years old\n* Estimated life expectancy of more than 3 months\n* ECOG performance status of 2 or lower\n* Adequate bone marrow function(absolute neutrophil count \\[ANC\\] \u22651,500/\u00b5L, hemoglobin \u22659.0 g/dL,and platelets \u2265100,000/\u00b5L)\n* Adequate kidney function (serum creatinine \\< 1.5 mg/dL)\n* Adequate liver function (serum total bilirubin \\< 2 times the upper normal limit (UNL); serum transaminases levels \\<3 times \\[\\<5 times for patients with liver metastasis\\] UNL)\n* No prior chemotherapy but prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed. (but, prior adjuvant chemotherapy with capecitabine or S-1 or camptothecin analogues was excluded)\n* No prior radiation therapy for at least 4 weeks before enrollment in the study\n* Must have minimum age of 18 Years\n* Must have maximum age of 70 Years",
                "exclusionCriteria": "* Other tumor type than adenocarcinoma\n* Central nervous system (CNS) metastases or prior radiation for CNS metastases\n* Gastric outlet obstruction or intestinal obstruction\n* Evidence of gastrointestinal bleeding\n* The patient has bony lesions as the sole evaluable disease.\n* Past or concurrent history of neoplasm other than stomach cancer, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri\n* Pregnant or lactating women, women of childbearing potential not employing adequate contraception\n* Other serious illness or medical conditions\n\n  * Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry\n  * History of significant neurologic or psychiatric disorders including dementia or seizures\n  * Active uncontrolled infection\n  * Other serious underlying medical conditions which could impair the ability of the patient to participate in the study\n* Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy\n* concomitant drug medication; The following drugs cause drug interaction with S-1.\n\n  i. Warfarin, phenprocoumon: increase bleeding tendency ii. Increase blood concentration of phenytoin iii. sorivudine: inhibit DPD -\\> increase toxicity according to fluoropyrimidine iv. allopurinol : decrease activity of S-1"
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT00312429",
                "officialTitle": "Cord Blood Transplantation in Adult Recipients"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Diagnosis reviewed at transplant center and confirmed to fit the criterion for high risk blood disease or cancer, as defined for the study\n* Estimated life expectancy of at least 6 weeks following study entry\n* Cancer and Leukemia Group B (CALGB) performance status less than or equal to 2\n* White blood cell count, platelet, hematocrit, tuberculosis, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, and HIV test results reviewed by transplant center\n* Multiple gated acquisition (MUGA), echocardiogram, cardiac MRI, and/or pulmonary function tests (PFT) performed and reviewed by transplant center (for individuals with an ejection fraction and diffusing capacity \\[DLCO\\] of 40-50%, the appropriate cardiology or pulmonary consultations should be considered if the individual has severe heart or lung disease at the initiation of therapy)\n* Sufficient number of umbilical cord blood units available for transplantation\n* If female, willing to use contraception throughout the study\n* Must have minimum age of 18 Years\n* Must have maximum age of 70 Years",
                "exclusionCriteria": "* Undergoing Interleukin-2 (IL-2) therapy within 8 weeks of study entry\n* Diagnosed with a medical or psychiatric illness that may interfere with study participation\n* Pregnant"
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT00319748",
                "officialTitle": "Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Adequate performance status:\n\n  * Breast - Karnofsky score \\> 50;\n  * Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score \u22642\n* If female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation.\n* Normal organ function within 14 days of study entry\n* Diagnosis of one of the following malignancies:\n\n  * Metastatic breast cancer (BR)\n  * Metastatic ovarian cancer (OV)\n  * Metastatic endometrial cancer (EM)\n  * Metastatic cervical cancer (CX)\n\nBreast Cancer Inclusion Criteria:\n\n* Measurable metastatic disease (\\>1cm) in at least one site other than bone-only\n* Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease\n* Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive. If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen.\n\nOvarian Cancer Inclusion Criteria:\n\n* Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)\n* Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma).\n* Subjects must have failed at least two previous chemotherapy regimens. Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens.\n\nEndometrial Cancer Inclusion Criteria:\n\n* Measurable metastatic disease\n* Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens\n\nCervical Cancer Inclusion Criteria:\n\n* Measurable metastatic disease\n* Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens.\n* Must have minimum age of 18 Years",
                "exclusionCriteria": "* Had/have the following prior/concurrent therapy:\n\n  * Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A (topical or inhaled steroids are allowed)\n  * Investigational drugs/agents within 14 days of first dose of 852A\n  * Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A (nitrosoureas within 30 days of first dose)\n  * Drugs known to induce QT interval prolongation and/or induce Torsades de pointes unless best available drug required to treat life-threatening conditions\n  * Radiotherapy within 3 weeks of the first dose of 852A\n  * Hematopoietic cell transplantation within 4 weeks of first dose of 852A\n  * Evidence of active infection within 3 days of first dose of 852A\n  * Active fungal infection or pulmonary infiltrates (prior treated disease stable for 2 weeks is allowable)\n  * Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication\n  * History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk\n  * Uncontrolled intercurrent or chronic illness\n  * Active autoimmune disease requiring immunosuppressive therapy within 30 days\n  * Active coagulation disorder not controlled with medication\n  * Pregnant or lactating\n  * Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated\n  * Any history of brain metastases or any other active central nervous system (CNS) disease"
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT00356148",
                "officialTitle": "Phase IV Study of Determining the Efficacy of Ampicillin/Sulbactam Combination as Antibiotic Prophylaxis During Breast Cancer Surgery in Patients With a Body Mass Index (BMI) Over 25."
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II.\n* Must be FEMALE\n* Must have minimum age of 18 Years",
                "exclusionCriteria": "* Ductal carcinoma in situ (DCIS; stage 0 cancer),\n* Advanced or distant metastatic stage,\n* Receiving any neoadjuvant therapy,\n* History of receiving any antibiotics within prior 3 months,\n* History of immunodeficiency,\n* Having a remote infection,\n* History of reaction to study antibiotics,\n* Denial of signing the consent form."
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT00344318",
                "officialTitle": "To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar\u2122, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Male or female between, and including, 6-12 weeks (42 to 90 days) of age at the time of the first vaccination.\n* Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol\n* Written informed consent obtained from the parent or guardian of the subject.\n* Free of obvious health problems as established by medical history and clinical examination before entering into the study.\n* Born after a gestation period between 36 and 42 weeks.\n* Must have minimum age of 6 Weeks\n* Must have maximum age of 12 Weeks",
                "exclusionCriteria": "* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3.\n* Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations\n* History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b diseases.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.\n* History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease.\n* Acute disease at the time of enrolment\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical\n* A family history of congenital or hereditary immunodeficiency.\n* Major congenital defects or serious chronic illness.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the active phase of the study."
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT00317148",
                "officialTitle": "Phase II-III Placebo-Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Healthy postmenopausal women with 50 or more moderate to severe hot flushes.\n* Women between 40 to 70 years of age.\n* Must be FEMALE\n* Must have minimum age of 40 Years\n* Must have maximum age of 70 Years",
                "exclusionCriteria": "* Body mass index (BMI) of 35 kg/m2 or more.\n* Significant metabolic and endocrine diseases.\n* Diagnosis of cancer.\n* Use of steroids or drugs that interfere with the metabolism of estrogen.\n* Use of any systemic estrogen, progestin, or DHEA in the eight weeks prior to randomization.\n* Use of alternative therapies or natural products to treat postmenopausal symptoms in the four weeks prior to randomization.\n* Palpable fibroids or uterine prolapse: Grade 2 or 3.\n* Cigarette smoking"
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT00305097",
                "officialTitle": "Effects of Caffeinated and Decaffeinated Coffee on Body Weight and Glucose Tolerance"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Aged at least 18 years with an ability and willingness to give written informed consent.\n* Body mass index 25-35 kg/m2\n* Users of at least 2 cups of caffeinated coffee per day who are willing to be randomized to any of the interventions.\n* Non-smoking\n* Must have minimum age of 18 Years",
                "exclusionCriteria": "* Any condition/illness that may affect the study outcomes or would make participation potentially harmful such as pregnancy or breastfeeding, diabetes mellitus, heart disease, stroke, hypertension, malabsorption syndromes, Gastroesophageal reflux disease GERD, a history of ulcer, according to a detailed medical history.\n* Abnormal hepatic function (liver function test \\> twice the normal range), abnormal renal function (creatinine \\> 1.1 mg/dl), fasting plasma glucose in the diabetic range (\\>/= 126 mg/dl), or blood pressure \\> 140/90 mmHg.\n* Present alcoholism or drug abuse or use of medications that could interfere with the treatment including bronchodilators, quinolone antibiotics, monoamine oxidase inhibitors, anxiolytics, ranitidine, corticosteroids, growth hormone, antihypertensives."
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT00351611",
                "officialTitle": "PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Epilepsy partial seizure subjects.\n* Currently taking 1 to 3 antiepileptic drugs.\n* Must have minimum age of 18 Years\n* Must have maximum age of 65 Years",
                "exclusionCriteria": "* Pre-existing eye diseases (glaucoma).\n* Insufficient response to pregabalin in the treatment of partial seizure, or patients currently receiving pregabalin treatment."
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT00279552",
                "officialTitle": "Can Recombinant Human Intrinsic Factor Be Used for Evaluation of the Vitamin B12 Absorption?"
            },
            "eligibilityModule": {
                "inclusionCriteria": "Patients suspected to have vitamin B12 deficiency defined as a plasma vitamin B12 below the reference interval (\\<200 pmol/L).\n* Must have minimum age of 18 Years",
                "exclusionCriteria": "Patients who were pregnant, nursing or not able to give written informed consent were excluded."
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT00324363",
                "officialTitle": "Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Treated with a stable dose of one of the following for at least 3 months prior to screening: \\* \\>=1000 mg/day immediate-release metformin; or metformin \\>=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy.\n* HbA1c between 7.1% and 11.0%, inclusive.\n* Body Mass Index (BMI) \\>21 kg/m\\^2 and \\<35 kg/m\\^2.\n* Must have minimum age of 21 Years\n* Must have maximum age of 75 Years",
                "exclusionCriteria": "* Have participated in this study previously, or any other study using exenatide or GLP-1 analogs.\n* Have participated in an interventional, medical, surgical, or pharmaceutical study within 30 days of screening.\n* Have characteristics contraindicating metformin or sulfonylurea use.\n* Have been treated with exogenous insulin for more than 1 week within the 3 months prior to screening.\n* Have used drugs for weight loss within 1 month of screening."
            }
        }
    ]
}